CECOG performs high-quality clinical trials in Oncology.
For criteria for qualification of centers including requirements defined by Good Clinical Practice, please send an e-mail to cecog@cecog.at
Currently, the following protocols are being performed:
- CECOG/BC.1.3.005
A randomized phase III trial of Paclitaxel plus Bevacizumab versus Capecitabine plus Bevacizumab for the first line treatment of HER2-negative locally recurrent or metastatic breast cancer.
- CECOG/CORE.1.2.002
(temporary enrollment stop. K-RAS will be assessed prospectively and thus the protocol will be amended accordingly).
A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX4 + weekly Cetuximab versus FOLFOX4 + bi-weekly Cetuximab as first-line therapy in patients with metastatic colorectal cancer.
- CECOG/DREAM (MO18420)
Phase III study of an optimized chomotherapy + Avastin ® Strategy + Tarceva ® in metastatic colorectal cancer. Optimox 3-Tarceva ® Study. C04-2.
For further information on inclusion and exclusion criteria, dosages
and schedules as well as other necessary information, please send
an e-mail to
cecog@cecog.at
top
© copyright 2001-2008, CENTRAL EUROPEAN COOPERATIVE ONCOLOGY GROUP
Coordinator: Univ. Prof. Dr. Christoph Zielinski, Schlagergasse 6/6, 1090 Vienna, Austria
all rights reserved